- World Pharma News Home » Clinical Trials » Tarceva brings new hope to patients with advanced non-small cell lung cancer
(a free service delivered by FeedBurner)
Roche has announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - , significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse.
1 Comment Add this link to... Bury
1 Comment Add this link to... Bury
Comments
Thousands of lung cancer patients could now live longer and better if they receive a new cancer treatment called Tarceva, a new lung cancer drug. The new lung cancer drug Tarceva works by blocking the complex inside the cell from uniting, so it can’t trigger the production of proteins inside the cell. This slows down the resulting cell division and halts the spread of cancer. For more information about lung cancer visit here http://www.asiasbestdoctors.com/doctor_story.php?storyid=161&id=4253